Literature DB >> 18472227

Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.

J R Brouwer1, E Severijnen, F H de Jong, D Hessl, R J Hagerman, B A Oostra, R Willemsen.   

Abstract

The human FMR1 gene contains an unstable CGG-repeat in its 5' untranslated region. The repeat length in the normal population is polymorphic (5-54 CGG-repeats). Individuals carrying lengths beyond 200 CGGs (i.e. the full mutation) show hypermethylation and as a consequence gene silencing of the FMR1 gene. The absence of the gene product FMRP causes the fragile X syndrome, the most common inherited form of mental retardation. Elderly carriers of the premutation (PM), which is defined as a repeat length between 55 and 200 CGGs, can develop a progressive neurodegenerative syndrome: fragile X-associated tremor/ataxia syndrome (FXTAS). The high FMR1 mRNA levels observed in cells from PM carriers have led to the hypothesis that FXTAS is caused by a pathogenic RNA gain-of-function mechanism. Apart from tremor/ataxia, specific psychiatric symptoms have been described in PM carriers with or without FXTAS. Since these symptoms could arise from elevated stress hormone levels, we investigated hypothalamic-pituitary-adrenal (HPA) axis regulation using a knock-in mouse model with an expanded CGG-repeat in the PM range (>98 repeats) in the Fmr1 gene, which shows repeat instability, and displays biochemical, phenotypic and neuropathological characteristics of FXTAS. We show elevated levels of corticosterone in serum and ubiquitin-positive inclusions in both the pituitary and adrenal gland of 100-week-old animals. In addition, we demonstrate ubiquitin-positive inclusions in the amygdala from aged expanded CGG-repeat mice. We hypothesize that altered regulation of the HPA axis and the amygdala and higher stress hormone levels in the mouse model for FXTAS may explain associated psychological symptoms in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472227      PMCID: PMC4408208          DOI: 10.1016/j.psyneuen.2008.03.011

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  49 in total

1.  Dynamic changes in subcellular localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants.

Authors:  M Nishi; H Ogawa; T Ito; K I Matsuda; M Kawata
Journal:  Mol Endocrinol       Date:  2001-07

2.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

3.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

4.  Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study.

Authors:  Elan Louis; Carol Moskowitz; Michael Friez; Maria Amaya; Jean Paul G Vonsattel
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

5.  The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome.

Authors:  Rob Willemsen; Marianne Hoogeveen-Westerveld; Surya Reis; Joan Holstege; Lies-Anne W F M Severijnen; Ingeborg M Nieuwenhuizen; Mariette Schrier; Leontine van Unen; Flora Tassone; Andre T Hoogeveen; Paul J Hagerman; Edwin J Mientjes; Ben A Oostra
Journal:  Hum Mol Genet       Date:  2003-05-01       Impact factor: 6.150

6.  Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome.

Authors:  Claudia M Greco; Kultida Soontrapornchai; Juthamas Wirojanan; John E Gould; Paul J Hagerman; Randi J Hagerman
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

7.  Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse.

Authors:  C E Bakker; Y de Diego Otero; C Bontekoe; P Raghoe; T Luteijn; A T Hoogeveen; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2000-07-10       Impact factor: 3.905

8.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

9.  Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated Fragile X full mutation.

Authors:  J R Brouwer; E J Mientjes; C E Bakker; I M Nieuwenhuizen; L A Severijnen; H C Van der Linde; D L Nelson; B A Oostra; R Willemsen
Journal:  Exp Cell Res       Date:  2006-10-13       Impact factor: 3.905

10.  Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome.

Authors:  Peng Jin; Ranhui Duan; Abrar Qurashi; Yunlong Qin; Donghua Tian; Tracie C Rosser; Huijie Liu; Yue Feng; Stephen T Warren
Journal:  Neuron       Date:  2007-08-16       Impact factor: 17.173

View more
  42 in total

1.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

Review 2.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

3.  Mouse models of the fragile x premutation and the fragile X associated tremor/ataxia syndrome.

Authors:  Michael R Hunsaker; Gloria Arque; Robert F Berman; Rob Willemsen; Renate K Hukema
Journal:  Results Probl Cell Differ       Date:  2012

Review 4.  A review of fragile X premutation disorders: expanding the psychiatric perspective.

Authors:  James A Bourgeois; Sarah M Coffey; Susan M Rivera; David Hessl; Louise W Gane; Flora Tassone; Claudia Greco; Brenda Finucane; Lawrence Nelson; Elizabeth Berry-Kravis; Jim Grigsby; Paul J Hagerman; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2009-05-05       Impact factor: 4.384

Review 5.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

6.  Progressive spatial processing deficits in a mouse model of the fragile X premutation.

Authors:  Michael R Hunsaker; H Jürgen Wenzel; Rob Willemsen; Robert F Berman
Journal:  Behav Neurosci       Date:  2009-12       Impact factor: 1.912

7.  Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.

Authors:  P E Adams; J S Adams; D V Nguyen; D Hessl; J A Brunberg; F Tassone; W Zhang; K Koldewyn; S M Rivera; J Grigsby; L Zhang; C Decarli; P J Hagerman; R J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-04-05       Impact factor: 3.568

Review 8.  Fragile X: a family of disorders.

Authors:  Weerasak Chonchaiya; Andrea Schneider; Randi J Hagerman
Journal:  Adv Pediatr       Date:  2009

9.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

10.  Immune-mediated disorders among women carriers of fragile X premutation alleles.

Authors:  Tri Indah Winarni; Weerasak Chonchaiya; Tanjung Ayu Sumekar; Paul Ashwood; Guadalupe Mendoza Morales; Flora Tassone; Danh V Nguyen; Sultana M H Faradz; Judy Van de Water; Kylee Cook; Alyssa Hamlin; Yi Mu; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2012-08-17       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.